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Abstract
Background: There is ample evidence from observational prospective studies that maternal depression or anxiety
during pregnancy is a risk factor for adverse psychosocial outcomes in the offspring. However, to date no previous
study has demonstrated that treatment of depressive or anxious symptoms in pregnancy actually could prevent
psychosocial problems in children. Preventing psychosocial problems in children will eventually bring down the
huge public health burden of mental disease. The main objective of this study is to assess the effects of cognitive
behavioural therapy in pregnant women with symptoms of anxiety or depression on the child’s development as
well as behavioural and emotional problems. In addition, we aim to study its effects on the child’s development,
maternal mental health, and neonatal outcomes, as well as the cost-effectiveness of cognitive behavioural therapy
relative to usual care.
Methods/design: We will include 300 women with at least moderate levels of anxiety or depression at the end of
the first trimester of pregnancy. By including 300 women we will be able to demonstrate effect sizes of 0.35 or
over on the total problems scale of the child behavioural checklist 1.5-5 with alpha 5% and power (1-beta) 80%.
Women in the intervention arm are offered 10-14 individual cognitive behavioural therapy sessions, 6-10 sessions
during pregnancy and 4-8 sessions after delivery (once a week). Women in the control group receive care as usual.
Primary outcome is behavioural/emotional problems at 1.5 years of age as assessed by the total problems scale of
the child behaviour checklist 1.5 - 5 years.
Secondary outcomes will be mental, psychomotor and behavioural development of the child at age 18 months
according to the Bayley scales, maternal anxiety and depression during pregnancy and postpartum, and neonatal
outcomes such as birth weight, gestational age and Apgar score, health care consumption and general health
status (economic evaluation).
Trial Registration: Netherlands Trial Register (NTR): NTR2242
Background
The burden of mental disorders is huge and at least
comparable to the burden caused by many severe physi-
cal diseases. In the WHO Global Burden of Disease pro-
ject it was estimated that 50% of all daily adjusted life
years (DALY’s) in the 15-44 years old are due to nine
psychiatry-related conditions [1]. Depressive disorders
are projected to rank second on a list of 15 major
diseases in terms of burden of disease in 2030 [2]. In
addition, a substantial part of the costs are caused by
new cases, which accounts for 39.2% of the costs at
population level [3]. Therefore, prevention of mental
disorders is essential.
Maternal anxiety or depression during pregnancy is an
important and potentially modifiable risk factor for cog-
nitive, behavioural and emotional problems in her chil-
dren [4-8]. Around 10-20% of all women are suffering
from depression or anxiety during pregnancy [9-12].
The magnitude of the effects of maternal anxiety or
depression on the child’s psychosocial problems is
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any medium, provided the original work is properly cited.considerable: it is estimated that up to 22% of the var-
iance in behavioural problems is linked with prenatal
anxiety, stress or depression [6]. The adverse effects
seem to be lasting. For example, antenatal anxiety of the
mother was related to behavioural or emotional pro-
blems of 4 year old children, independent of the
mother’s postnatal depression or anxiety [4], and higher
anxiety levels of the mothers early in pregnancy were
related to an increase in ADHD and other externalizing
problems in their 8-9 year old children [13].
There are several ways in which depression or anxiety
during pregnancy could have an adverse effect on the
offspring. These ways can be divided in direct and indir-
ect ways.
In the direct way, depression activates the maternal
stress system leading to elevated cortisol levels, which
might influence the development of the foetus’ brain by
passing the placenta.
An indirect adverse effect might be another mechan-
ism, because women who suffer from antenatal depres-
s i o nh a v et h et e n d e n c yt ot a k el e s sg o o dc a r eo f
themselves (e.g. neglecting personal hygiene, sleeping
problems, disturbed drinking and smoking habits, deny-
ing prenatal care). These consequences might all influ-
ence the development of the foetus [14-17].
Another indirect way in which depression might influ-
ence the offspring is when the antenatal depression
remains after delivery and turns into a postnatal depres-
s i o n .I nt h i sw a y ,m o t h e r - child attachment might be
endangered, because the mother has a reduced ability to
respond to the child. Children from depressed mothers
have a higher risk on insecure attachment, which in
turn is associated with cognitive, behavioural and emo-
tional problems [1,18-20].
Finally, the association between antenatal depression
and adverse outcomes in the offspring might be
explained by genetic predisposition in both mother and
child.
The effectiveness of psychological therapy in the treat-
ment of both anxiety and depression has been shown in
the past 50 years, especially for cognitive behavioural
therapy (CBT) [21-25]. Although guidelines state that
m e d i c a t i o ni sa na l t e r n a t i v eeffective treatment, the
safety of antidepressants during pregnancy remains inse-
cure [26].
Still, it is too early to implement CBT for depressed or
anxious women to prevent psychosocial problems in the
offspring. This is because in the development of such a
preventive strategy, demonstration of the causality and
size of the effect of the reduction of symptoms of
depression and anxiety on child outcomes is a crucial
step, a step that has not been taken to date. This knowl-
edge gap will be filled by the results of the present
experimental study.
Whatever the actual mechanisms involved are, there is
presently convincing evidence that children whose
mothers suffered from anxiety or depression during
pregnancy constitute a high risk group for behavioural
and emotional problems. On population level, substan-
tial total mental health gains may be accomplished
when depressed or anxious women are adequately trea-
ted during their pregnancy, even if the effect size of the
treatment is relatively small.
We will perform a randomized controlled trial (RCT)
in pregnant women with symptoms of depression or
anxiety to study the effect of CBT as compared to care
as usual (CAU) on the offspring’s behavioural and emo-
tional problems.
In the CBT arm, we expect more beneficial neonatal
outcomes, in particular higher birth weight and less pre-
maturity, which are risk factors for adverse cognitive
and behavioural outcomes themselves [8]. We also
anticipate reduced smoking and less drinking, with
many physical and mental health benefits for the child
as a result [17]. Since prenatal depression has shown to
be related to postnatal depression, we hypothesize that
our intervention will also counter postnatal depression,
which in turn will benefit the mother - child attachment
[27].
Finally, but not unimportantly, the reduction of symp-
toms of anxiety or depression during pregnancy and the
early postnatal period is valuable in itself. It may further
provide for a safer approach to reducing symptoms in
pregnancy than antidepressant medication [15]
To date, no such study has been performed.
Methods/Design
Objective
The aim of this study is to examine the effect of cogni-
tive behavioural therapy (CBT) in women with at least
moderate symptoms of anxiety and/or depression at the
end of the first trimester of pregnancy, on the extent of
total behavioural and emotional problems in their chil-
dren at 1.5 years of age, as compared with care as usual
(CAU).
Setting & Design
The source population will consist of all pregnant
women in the Netherlands in the first trimester of their
pregnancy. Women are recruited in obstetric care. In
addition, we will invite pregnant women through adver-
tisements in regional and national media targeted at
pregnant women.
Women will be screened on anxiety and depression
symptoms. Women with at least moderate symptoms of
anxiety and/or depression at the end of the first trime-
ster of pregnancy are either randomized to the interven-
tion group in which they receive 10-14 sessions of CBT,
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usual.
Figure 1 shows the exact design of the study.
Study outcome measures
The primary outcome in this project is the total emo-
tional and behavioural problems score of the child
according to the Child Behaviour Check List 1.5 - 5
(CBCL 1.5-5) at 18 months of age.
Secondary outcomes are the child’sm e n t a la n dp s y -
chomotor development at 18 months of age, the change
in depressive and anxious symptoms in the mother,
obstetric variables such as birth weight, gestational age
and Apgar score, the socio-demographic and lifestyle
factors, such as alcohol use, smoking and education, and
cost-effectiveness of the therapy.
Sample size
Studies on the prevention of mental disorders tend to
suffer from problems of insufficient statistical power [28].
I nt h ec u r r e n ts t u d yw ea i mt og e ta r o u n dt h i sp r o b l e m
by using a continuous primary outcome measure and by
including a high risk group (selective prevention).
We decided that effect sizes of 0.35 (midpoint of small
- medium effect size) or over on the total problems
scale of CBCL 1.5-5 are to be detected. With alpha 5%
and power (1-beta) 80%, we have to include 260
participants in our analyses. To account for some drop
out we aim at 300 women entering the trial. If 50%
eventually meets all criteria and gives informed consent,
600 screen-positives must be identified. The 50% rate is
based on studies with psychological interventions during
pregnancy aimed at reducing the occurrence of postna-
tal depression [27]. Given the figures in the literature
[11,29] we can expect around 10% screen-positives on
either the anxiety or depression screener. With an esti-
mated 50% comorbidity between anxiety and depression
this means that approximately 15% will be eligible for
the randomisation. Therefore, 4000 need to be screened.
Assuming a response rate of 75% [30] this implies that
5333 must be offered screening. To be on the safe side,
we aim at screening 6000 women. If necessary for the
recruitment of 300 women, the total number of screens
may be increased.
Inclusion
Women in obstetric care in the Netherlands with a sig-
nificant level of anxiety (6 item STAI > = 42) or at least
moderate depressive symptoms (EPDS > = 12) in their
first trimester are invited to participate in the trial.
Exclusion
Women fulfilling one or more of the following criteria
will be excluded from participation:
1. Multiple pregnancy. We decided to exclude
women with multiple pregnancy as they have a
markedly increased obstetric risk; inclusion will
threaten the homogeneity of the study population
and thereby decrease the sensitivity to detect effects.
2. High suicidal risk according to the suicidality sub-
scale score on the MINI International Neuropsychia-
tric Interview (MINI, defined as a positive response
on the question on concrete suicide plans)
3. Presently receiving psychotherapy
4. Substantial physical disease or illegal substance
abuse
5. No mastery of the Dutch language
6. Having a psychiatric history on bipolar disorder,
psychoses and manic disorder
7. History of in vitro fertilization
Assessments
Women will be asked to fill in questionnaires until their
child is 1.5 years. This will be done at 8 occasions: the
screener at baseline (T0), the additional baseline infor-
mation (T1), and follow-up questionnaires at 24 and 36
weeks of gestation (T3 and T4), at 6 weeks postpartum
(T5), 6 months postpartum (T6), 12 months postpartum
(T7) and 18 months postpartum (T8).
Figure 1 Flow diagram.
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monitored by the 6-item StateT r a i tA n x i e t yI n v e n t o r y
(STAI) and the Edinburgh Postnatal Depression Scale
(EPDS). As to be found in table 1, all other question-
naires can be filled in once or at several time points.
For anxiety, we use the Dutch version of the 6-item
STAI. This self report questionnaire is as valid as the full
20-item version and has frequently been used to measure
antenatal anxiety [29]. For the screening on depression
we use the EPDS, which has 10 items [31]. This is the
most frequently used self report depression screener in
the postnatal period as well as during pregnancy and has
been found particularly valid during pregnancy because
this scale omits somatic symptoms [30].
The following information will be obtained from parti-
cipants. The exact time of administration can be found
in table 1.
￿ Life events before pregnancy will be assessed at
baseline, using the Negative Life Events Question-
naire [NLEQ, [32]].
￿ Perceived social support will be measured accord-
ing to the 9-item Social Support Questionnaire
(SSQ)-short form [33].
￿ General health, socioeconomic position, ethnicity,
smoking behavior, alcohol use, psychiatric history
(whether the participant has had depression and/or
anxiety symptoms before, whether she was treated
for this and whether she is presently in treatment
for these symptoms) will be assessed. Socioeco-
nomic position will be assessed using five indica-
tors: family income, educational level (father and
mother), and occupational level (father and
mother). This questionnaire is based on a question-
naire used in the Utrecht Health Project (Dutch
acronym LRGP: Leidsche Rijn Gezondheids Project,
http://www.zorggegevens.nl/zorg/eerstelijnszorg/
leidsche-rijn-gezondheidsproject/). General health
status will also be taken into account according to
the EQ-5D [34].
￿ Personality will be assessed using the NEO Five
Factor Inventory (NEO-FFI). The NEO-FFI is a shor-
t e n e dv e r s i o no ft h eN E O - P R - I[ 3 5 ]a n dc o v e r st h e
Big Five of personality (neuroticism, extraversion,
openness, altruism and conscientiousness). These
aspects each contain 6 subscales. The NEO-FFI con-
tains 60 questions, 2 on each subscale. The present
study will add 4 full subscales to the short version;
two subscales of neuroticism, one of extraversion
and one of conscientiousness. This is because we
expect them to have the strongest association with
persistence of depression and/or anxiety. The NEO-
FFI is translated and validated in Dutch [36].
￿ Information on previous pregnancies, family size
and composition, pregnancy related life events and
on reactions on becoming a parent will be adminis-
tered using questionnaires from the ALSPACstudy
(http://www.bristol.ac.uk/alspac).
￿ Suicide risk will be measured using six screening
questions from the MINI International Neuropsy-
chiatric Interview [MINI, [37]].
￿ Maternal attachment style will be measured
according to the ECR [38], which has been trans-
lated and validated for the Netherlands by Conradi
et al. [39].
￿ Health care consumption will be assessed based on
the TIC-P [40]. This instrument allows reliable recall
over the past 6 months [41].
￿ Coping style will be assessed using the Utrechtse
Coping Lijst, the UCL [42].
￿ A Dutch version of the Dysfunctional Attitude
Scale (DAS) will be used to measure cognitions and
attitudes [43].
￿ Obstetric variables such as gestational age, birth
weight, Apgar score, complications such as (pre)
eclampsia or HELLP, which will be obtained from
midwifes. Women will be asked to give consent for
this.
￿ Finally, we will use the SCID-I to screen for a pos-
sible clinical depressive or anxiety disorder [44]. The
Table 1 Assessments per measurement
T0 T1 T2 T3 T4 T5 T6 T7
Depression (EPDS) XXXXXXXX
Anxiety (STAI) XXXXXXXX
Personality NEO-FFI XXX
Life events before pregnancy
(NLEQ)
X
Life events during pregnancy XXX
Perceived social support (SSQ) X
Coping styles (UCL) XXXX
Attitudes (DAS) XXXX
Maternal attachment (ECR) XX
Quality of life (EQ-5D) XXXXXX
Sociodemographic & -economic
factors
X
Lifestyle XXX
Breastfeeding X
General health X
Health care consumption X XXX
Previous pregnancies X
Suicidality (MINI) X
Clinical Diagnostic Interview
(SCID-II)
X
Child Behaviour (CBCL) X
Child development (BSID-II) X
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taken in a personal interview.
Besides questionnaires for the mother during her
pregnancy and the first 1.5 years postpartum, there will
be assessments in the child at 1.5 years of age.
One of the assessments is the Bayley Scale of Infant
Development (BSID-II) [45]. This is a formal neuropsy-
chological tool to assess the developmental level of a
child between 1 and 42 months. It is individually admi-
nistered by one of the researchers and consists of 3 sub-
scales: cognitive development (mental development
index), gross and fine motor development and the beha-
vioural rating scale. This tool is widely used in both
research and clinical settings and is considered the best
and most applied method for the assessment of the
child’s development to date [46]. Importantly, the instru-
ment has shown to be sensitive. In the context of our
proposal, maternal anxiety in pregnancy explained as
much as 11% of the variance in the Bayley scores in a
study among two year old toddlers by LaPlante et al. [47].
The second assessment is the Child Behaviour Check
List 1.5 - 5 (CBCL 1.5-5) including the Caregiver-Tea-
cher Report form (C-TRF) and the Language Develop-
ment Survey (LDS) [48]. This well established, reliable
and valid scale designed for parents and caregivers com-
prises seven syndrome scales: emotionally reactive,
anxious depressed, somatic complaints, withdrawn, sleep
problems, attention problems and aggressive problems.
In addition, it contains scales for internalizing, externa-
lizing and total problems. Symptom scores may further
be related to formal DSM-diagnostic criteria. The LDS
provides a screen for delays in vocabulary and word
combinations.
For the assessment of psychopathology in preschool
children it is essential to obtain information from differ-
ent sources [49]. Therefore we decided to include the
C-TRF for the caregivers of the children other than
their parents. Parents will be asked to hand these lists to
the actual caregivers of their children, e.g. grandparents,
baby-sitters, kindergarten-coaches, et cetera. Relevant in
this respect, a review by Skovgaard [46] underlined the
significance of both the developmental aspects (e.g. as
measured with the BSID II) and the infant caregiver
relation in the assessment of children 0-3 years of age.
The CBCL has been used successfully in several stu-
dies, amongst others on externalizing problems [50]. It
has been translated and standardized for use in around
60 countries, including the Netherlands. The CBCL 1.5-
5 is considered a sensitive instrument also deployed in
current intervention studies [51,52]
Also, mother-child interaction will be measured by
taping them for 15 minutes on video and scoring them
afterwards on interaction points.
All assessors of both handling questionnaires filled in
by the mother and measuring the children at age 1,5 are
blinded for treatment assignment.
Additional baseline data
Women agreeing to participate will be asked to provide
additional baseline data at T1, as to find in table 1.
About half of these questionnaires are sent to the par-
ticipants in print, the other half can be answered online.
All follow-up questionnaires are available online.
After providing baseline data both in print and online,
women are telephoned for the Structured Clinical Inter-
view for DSM-II Disorders (SCID-VI). The SCID-II will
allow us to study treatment effects additionally accord-
ing to diagnostic categories rather than symptom levels.
Randomisation
Right after the SCID-II interview, women are rando-
mised 1:1 to either CBT or CAU.
We will create randomisation lists, stratified for parity
and socio-economic position, with randomly permuted
blocks of random size.
Women randomized to the CAU arm will be informed
about being at risk of depression or anxiety disorder by
the researchers and will be advised to contact their GP.
A close record will be kept of all care provided in the
CAU arm.
CBT Intervention
The intervention consists of 10-14 individual sessions: 6-
10 sessions during pregnancy and 4-8 sessions after
delivery (once a week). The CBT will be conducted by
registered psychologists, specialized in conducting CBT.
CBT posits that an individual’s biased information
processing leads to maladaptive feelings and behaviours
which can culminate in psychological distress and even-
tually in psychiatric disorders. The main focus of the
proposed intervention is targeted on identifying and
changing dysfunctional cognitions and schemata (atti-
tudes) specifically for pregnant depressed and anxious
patients. In CBT, the Socratic dialog is used aiming to
change these dysfunctional cognitions and attitudes per-
manently. CBT may therefore result in long term pro-
tection against psychosocial problems. It is therefore not
surprising that cognitive therapy during the acute phase
of depression also appears to be effective in reducing
subsequent recurrence rates [25].
The first session will focus on the rationale CBT, i.e.
the influence of (irrational or dysfunctional) cognitions
and attitudes on feelings and behaviours. Additionally,
goal setting will be initiated. These therapy goals will be
unique for each patient. The subsequent sessions will be
targeted at identifying and amending irrational cogni-
tions and attitudes related to pregnancy, delivery,
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situation. Each session will address specific pregnancy-
related cognitions. Additionally, patients will be taught
how dysfunctional cognitions and attitudes affect
adversely feelings and behaviours.
These dysfunctional cognitions and attitudes will be
challenged and replaced by functional cognitions and
attitudes. After each session, patients will be given home
work. For example, patients will be asked to register
negative experiences, and accompanying cognitions, feel-
ings and behaviours. Finally, in the last two to four ses-
sions, the newly learned cognitions and attitudes will be
consolidated.
Data analysis
If necessary, skewed continuous variables will be trans-
formed to normality prior to the analyses. The primary
outcome, i.e. the CBCL scores at month 18, will be
compared between the treatment arms using the
unpaired t-test. This test will also be used for detecting
differences in the Bayley scores by month 18 and the
obstetric variables measured at birth. The latter group
of variables will be tested using the Chi2 test if categori-
cal. Differences in attachment style at month 12 will be
analyzed using analysis of covariance with the baseline
variable as a covariate. Continuous outcomes that were
measured more than twice (e.g. EPDS and STAI) will be
analyzed as dependent variables using linear mixed
models for fixed and random effects. These models are
superior for the analysis of longitudinally correlated data
and can optimally deal with missing values [53]. A
mixed model ascribes a unique intercept and slope esti-
mate to each individual, while making use of informa-
tion across individuals for predicting these quantities. In
t h e s ea n a l y s e s ,at r e a t m e n t * t i m ev a r i a b l ei n d i c a t i n gt h e
effect of the intervention will be included as an indepen-
dent variable. If despite randomisation important base-
line differences exist in prognostically important
variables such as the extent of social support or history
of life events, they will be adjusted for. Additional ana-
lyses will be conducted to demonstrate mediation of the
effect of CBT on the child’s outcomes by maternal
symptom level, alcohol or nicotine consumption in
pregnancy, medication use or neonatal outcomes.
The analyses will primarily be carried out according to
the intention-to-treat (ITT) principle, i.e. the partici-
pants will be analyzed according to their randomized
allocation, regardless of the actual CBT undergone, or
time in study after baseline. Aside from the optimal
validity of ITT analyses, they quantify the effects on the
outcome measures that would be obtained in practice.
The magnitude of the effect measured in an ITT analy-
sis incorporates the effects caused by non-adherence to
CBT, behavioural changes, et cetera. Secondary analyses
will be of the ‘per protocol’ type meaning that they will
be restricted to those women that had all of the CBT
sessions.
Considering specific target populations, there is evi-
dence that the socio-economically deprived may have
more benefit from treatment of depression during preg-
nancy [15]. Therefore, subgroup analyses will be under-
taken according to socio-economic position. Subgroup
analyses will also be undertaken according to parity.
Differences in effect of CBT between subgroups will
be statistically evaluated by testing treatment by sub-
group interaction terms. Effect parameters will be sup-
plied with a 95% confidence interval.
Economic evaluation
An economic evaluation will be conducted alongside the
trial to assess the cost-effectiveness of CBT compared to
care as usual in the current study population. Informa-
tion on costs and health outcomes will be prospectively
collected during 24 months (starting at baseline until 18
months after birth) for both mother and child. Two
complementary economic analyses will be conducted.
The primary outcome measure of the planned cost-
effectiveness analysis is the total emotional and beha-
vioural problems score of the child according to the
CBCL at 18 months of age.
In the additionally planned cost-utility analysis,
QALYs (Quality Adjusted Life Years) will be used as the
primary outcome measure. The study will be performed
from a societal perspective. Medical costs that will be
assessed include costs related to CBT, contacts with
healthcare professionals, and medication use. Outside
the healthcare sector, costs of informal care and produc-
tivity losses will be taken into account. Unit prices will
largely be based on Dutch standard prices in order to
facilitate comparisons with other economic evaluations.
Cost-effectiveness acceptability curves will be used to
inform decision-makers on the probability that the stu-
died intervention is cost-effective.
This study protocol was approved by the medical ethi-
cal committee of the University Medical Centre
Groningen.
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